medigene.com
Medigene - HomeMedigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.
http://www.medigene.com/
Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.
http://www.medigene.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
2.7 seconds
16x16
32x32
MediGene AG
Joachim Beck
Lochha●●●●●●aße 11
Mart●●●●ried , DE, 82152
DE
View this contact
MediGene AG
Joachim Beck
Lochha●●●●●●aße 11
Mart●●●●ried , DE, 82152
DE
View this contact
BioLink Informationstechnologie GmbH
BioLink Hostmaster
Lochha●●●●●●raße 9
Planeg●●●●●●nsried , Bayern, 82152
DE
View this contact
BUY YOUR DOMAIN
26
YEARS
3
MONTHS
3
DAYS
PSI-USA, INC. DBA DOMAIN ROBOT
WHOIS : whois.psi-usa.info
REFERRED : http://www.psi-usa.info
PAGES IN
THIS WEBSITE
15
SSL
EXTERNAL LINKS
42
SITE IP
185.64.113.77
LOAD TIME
2.691 sec
SCORE
6.2
Medigene - Home | medigene.com Reviews
https://medigene.com
Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.
Medigene AG ANNUAL REPORT 2014 - clinical-stage immunotherapies
Letter to the Shareholders. Financial Report and Service. Immunotherapies are being researched and developed worldwide as innovative methods for treating cancer. Medigene’s immunotherapies are based on targeted strengthening of the immune system, using the body’s own defence mechanisms, and are currently being tested in clinical trials for the benefit of critically ill patients. We are working on making the body’s own T cells usable in fighting serious diseases. With its most advanced immunotherapy platf...
Medigene AG ANNUAL REPORT 2014 - Inspired by immunotherapies
Financial Report and Service. The innovative approach of immunotherapy is regarded as crucial new-generation future technology for the treatment of cancer and other serious diseases. Immunotherapy specifically strenghens the immune system, using the body’s own defence mechanisms. Dedicated to advance these innovative approaches to help patients who are seriously ill, we are working at harnessing T-cells to combat serious diseases. Medigene has positioned itself in the area of personalised immunotherapies.
medigene.com
Pipeline | Medigene AG
https://www.medigene.com/products-pipeline/pipeline
Phase II part of ongoing CD study in leukemia (AML) initiated. Clinical development of TCRs in preparation. DC platform and TCR platform strengthened by new patents. Medigene is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The company concentrates on the development of personalized T cell-based immunotherapies.
Imprint | Medigene AG
https://www.medigene.com/imprint
Stärkung des Patentportfolios rund um unsere Immuntherapien. Präsentation klinischer Daten mit DC-Vakzinen durch Partner. Lochhamer Str. 11. Prof Dr. Dolores Schendel (Chief Executive Office, Chief Scientific Officer). David Lemus (Chief Operating Officer). Responsible for the webpage:. Value added tax id.
Financial Calendar | Medigene AG
https://www.medigene.com/media-investors/events/financial-calendar
Targeted increase in research and development expenses for immunotherapies of 68%. Financial forecast for 2016 confirmed. EBITDA improved by 6%.
Corporate Governance | Medigene AG
https://www.medigene.com/media-investors/corporate-governance
Declaration on Corporate Governance. Targeted increase in research and development expenses for immunotherapies of 68%. Financial forecast for 2016 confirmed. EBITDA improved by 6%. Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our sharehol...
Links | Medigene AG
https://www.medigene.com/links
Stärkung des Patentportfolios rund um unsere Immuntherapien. Präsentation klinischer Daten mit DC-Vakzinen durch Partner. Clinical trial and treatments for brain tumors. American Brain Tumor Association. BioSpace: Biotechnology and Pharmaceutical News. Employment links for the biomedical scientist. All the Virology: Table of Contents. EBE (Emerging Biopharmaceutical Enterprises).
TOTAL PAGES IN THIS WEBSITE
15
Tumor Vaccine: AAVLP
http://www.biomed.cc/r-d
Cancer is an increasing threat with a great demand for novel, improved therapies. Vaccines can help the patient to build up own protective immunity. In a joint project, MediGene. Martinsried, Germany, and Biomed developed a new generation of anti-cancer vaccines targeted against the HER-2 molecule. Her-2 is expressed in breast cancer, but also on many other tumor entities such as ovarian and gastric cancer. WO2013037961 (A1) - 2013-03-21. Anti-Her2 vaccine based upon AAV derived multimeric structures.
geschaeftsbericht2014.medigene.de
Medigene AG GESCHÄFTSBERICHT 2014 - Finanzbericht & Service - Impressum
http://www.geschaeftsbericht2014.medigene.de/finanzbericht-amp-service/impressum.html
Lochhamer Str. 11. Web: www.medigene.com. Public and Investor Relations. Julia Hofmann, Anja Clausnitzer. Dr Frank Mathias (Vorstandsvorsitzender). Prof Dolores Schendel (Vorstand für Forschung and Entwicklung). Medigene AG, Planegg/Martinsried. Konzept, Design und Umsetzung. Kirchhoff Consult AG, Hamburg. Kirchhoff Consult AG, Hamburg. Matthias Tunger, München. Arb limited, London. Ernst and Young GmbH Wirtschaftsprüfungsgesellschaft, Stuttgart. Ist eine Marke der Medigene AG. Mit der Nutzung unserer We...
BioM AG - bio-m.org
http://www.bio-m.org/biom-ag.html
Netzwerk - Ihr Cluster. AG Munich Biotech Development ist ein Beratungs- und Beteiligungsunternehmen mit Sitz in Martinsried im Zentrum der BioTech-Region München. Die Bio. AG unterstützt mit ihrem Seed-Finanzierungsprogramm junge und viel versprechende Biotechnologieunternehmen, insbesondere in der Gründungs- und der Start-up-Phase mit einem Schwerpunkt auf die medizinische Biotechnologie. Die Investments erfolgen aus dem Eigenkaptal der Bio. AG heraus. Die Bio. Zudem steht die Bio. AG über ein umfangre...
global-life-science-ventures.com
GLSV - Portfolio Companies
http://www.global-life-science-ventures.com/portfolio/index.html
Global Life Science Ventures — Investing in the life sciences. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation. Currenty, no new investments are being sought. Agendia B. V. Website: www.agendia.com. Nabriva Therapeutics GmbH,. Is a biopharmaceutical company engaged in ...
TOTAL LINKS TO THIS WEBSITE
42
Medigen Sp. z o.o. Podmiot Leczniczy - dobieramy najlepszych dawców szpiku
Medigen Sp. z o.o. Podmiot Leczniczy – dobieramy najlepszych dawców szpiku. Dobieramy najlepszych dawców szpiku. Wyprawa pacjentów leczonych przez Medigen z nominacją do Travelerów! Osiągnięcia Medigen Sp. z o.o. 1 Oznaczanie antygenów HLA. 3 Formalne przeszukanie rejestrów. 4 Oznaczanie antygenów HLA-DR. Nasi pacjenci, w ramach wyprawy „SZPIK NA SZCZYT”, zdobyli najwyższe wzniesienie Afryki (KIlimandżaro, 5895 m n.pm). Trudno o lepszy dowód na powrót do pełni życia po przeszczepie. W celu zapewnienia be...
МЕДИГЕН | Лабораторные принадлежности, молекулярная биология, биохимические реактивы, оборудование для лаборатории, реагенты
От пробирки до лаборатории. ДНК, ДНК-маркеры и олигонуклеотиды. Ферменты для молекулярной биологии. Зонды, цитощетки и транспортные среды. Расходные материалы для дезинфекции, стерилизации и утилизации. Расходные материалы для фильтрации. Принадлежности для работы с культурами клеток. Ламинарные шкафы и ПЦР-боксы. Шейкеры, ротаторы и мешалки. Наборы для выделения ДНК. Наборы для выделения РНК. ДНК, ДНК-маркеры и олигонуклеотиды. Ферменты для молекулярной биологии. Ламинарные шкафы и ПЦР-боксы. Телефон: 7...
Medigen Biosciences — Coming Soon
This page is used to test the proper operation of your recent MOJO Marketplace. If you can read this page it means your installation was successful! The owner of this website is working on making this site awesome. Why not bookmark it. And come back again later. We are sure you will not be disappointed. Are you the Site Owner? To your WordPress installation and prepare your site for launch. To launch your site just click the link in the banner at the top of the screen. Make My Site Look Like the Demo.
Medigence Home Healthcare
Home Healthcare in Cyprus is now. An option for all. Medigence is the first private home healthcare. Provider in Cyprus with nationwide coverage. And a solid reputation for delivering. 5 reasons to choose Medigence Home Healthcare Services. The specialized and experienced team of Medigence delivers a full range of state-of-the-art home healthcare services in the comfort of your own home, at affordable prices. The security and familiarity that a home provides, coupled with the high quality of Medigence Ho...
Medigene
Access to MEDIGENE PORTAL. Medicine & Anthropology. Concepts & objectives. Medicine & Anthropology. Concepts & objectives. The 3rd MEDIGENE annual meeting was held in Barcelona and Tarragona (organized by CIBER, IDIBAPS and ICAC). A focus was made on MetS in the different MEDIGENE populations. Genetic and environmental factors of insulin resistance syndrome and its long term complication in immigrant mediterranean populations. MEDIGENE Ancient DNA Biobank. Florin Grigorescu MD,. Phone 33 4 11 75 98 95.
Medigene - Home
Declaration on Corporate Governance. Contact / E-mail alert. Medical Director / Head of Clinical Development (m/f). Technical Assistant (m/f) Clinical Immune Monitoring. Scientist (m/f) Technology Innovation. Technical Assistant (m/f) Technology Innovation. Technical Assistant (m/f) Cell Therapy Process Development. We are empowering T cells to effectively fight cancer. Medigene publishes 2017 annual report and announces start of clinical trial with TCR immunotherapy MDG1011. Deeply rooted in Science.
Medigene - Startseite
Kontakt / E-Mail Benachrichtigungen. Medical Director / Head of Clinical Development (m/f). Technischer Assistent (m/w) Clinical Immune Monitoring. Scientist (m/w) Technology Innovation. Technischer Assistent (m/w) Technology Innovation. Technischer Assistent (m/w) Cell Therapy Process Development. Wir aktivieren T-Zellen, um Krebs zu bekämpfen. Medigene veröffentlicht Geschäftsbericht 2017 und gibt Studienstart mit TCR-Immuntherapie MDG1011 bekannt. Medigene präsentiert auf weiteren Konferenzen. Unser t...
Medigene Press |
Comunicación en Genética Médica. Descubre cómo podemos ayudarte. Medigene Press es una empresa dedicada a la edición, publicación y difusión de contenidos divulgativos, docentes y formativos relacionados con la medicina y la biomedicina, especializados en el ares de la Genética Médica y Genómica. Somos pioneros en el lanzamiento de la primera revista online de habla hispana en el ámbito de la Genética Médica y Genómica,. Con visión de futuro. Diseñado por Elegant Themes.
Medigenecenter.com
This domain may be for sale. Backorder this Domain. This Domain Name Has Expired - Renewal Instructions.
medigeneral.com - This domain may be for sale!
Find the best information and most relevant links on all topics related to medigeneral.com. This domain may be for sale!
Medigenerx.net
SOCIAL ENGAGEMENT